CASI CASI Pharmaceuticals Inc

Price (delayed)

$2.51

Market cap

$34.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$4.89M

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is ...

Highlights
CASI's gross profit has soared by 122% YoY and by 11% QoQ
The debt has dropped by 100% year-on-year
CASI Pharmaceuticals's quick ratio has plunged by 60% YoY and by 23% from the previous quarter
The equity has declined by 25% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of CASI
Market
Shares outstanding
13.61M
Market cap
$34.15M
Enterprise value
$4.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
1.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.15
Earnings
Revenue
$33.49M
EBIT
-$31.37M
EBITDA
-$28.4M
Free cash flow
-$33.32M
Per share
EPS
-$2.2
Free cash flow per share
-$2.42
Book value per share
$5.49
Revenue per share
$2.43
TBVPS
$8.53
Balance sheet
Total assets
$129.56M
Total liabilities
$30.85M
Debt
$0
Equity
$74.99M
Working capital
$38.82M
Liquidity
Debt to equity
0
Current ratio
3.8
Quick ratio
3.43
Net debt/EBITDA
1.03
Margins
EBITDA margin
-84.8%
Gross margin
58.3%
Net margin
-93.6%
Operating margin
-100.1%
Efficiency
Return on assets
-22.9%
Return on equity
-36.8%
Return on invested capital
-45.8%
Return on capital employed
-27.1%
Return on sales
-93.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CASI stock price

How has the CASI Pharmaceuticals stock price performed over time
Intraday
0.4%
1 week
4.15%
1 month
-14.63%
1 year
-97.89%
YTD
-96.86%
QTD
-12.24%

Financial performance

How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
$33.49M
Gross profit
$19.54M
Operating income
-$33.53M
Net income
-$31.37M
Gross margin
58.3%
Net margin
-93.6%
CASI's gross profit has soared by 122% YoY and by 11% QoQ
CASI's revenue has soared by 92% YoY and by 11% QoQ
The net margin has surged by 70% year-on-year and by 23% since the previous quarter
CASI's operating margin has soared by 70% YoY and by 28% from the previous quarter

Growth

What is CASI Pharmaceuticals's growth rate over time

Valuation

What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.46
P/S
1.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.15
CASI's EPS has surged by 52% year-on-year and by 19% since the previous quarter
The stock's P/B is 88% below its 5-year quarterly average of 3.7 and 74% below its last 4 quarters average of 1.8
The equity has declined by 25% year-on-year and by 11% since the previous quarter
CASI's revenue has soared by 92% YoY and by 11% QoQ
CASI's P/S is 82% below its last 4 quarters average of 5.8

Efficiency

How efficient is CASI Pharmaceuticals business performance
CASI's return on sales has surged by 70% year-on-year and by 23% since the previous quarter
CASI's ROIC has soared by 62% YoY and by 19% from the previous quarter
The ROA has grown by 46% YoY and by 11% from the previous quarter
The return on equity is up by 42% year-on-year and by 8% since the previous quarter

Dividends

What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CASI.

Financial health

How did CASI Pharmaceuticals financials performed over time
CASI Pharmaceuticals's quick ratio has plunged by 60% YoY and by 23% from the previous quarter
CASI Pharmaceuticals's current ratio has plunged by 57% YoY and by 19% from the previous quarter
The debt is 100% smaller than the equity
The debt has dropped by 100% year-on-year
CASI's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.